More than two-fifths (44%) of women with epilepsy say they have not discussed the risks of taking valproate during pregnancy with their healthcare professional in the last 12 months.
Stories about MHRA
This week, the Medicines and Healthcare products Regulatory Agency (MHRA) is running a campaign to raise awareness of reporting medicine side-effects.
Three of the UK’s epilepsy charities have created a survey to assess how aware women aged 16-50 are about the possible risks of taking sodium valproate during pregnancy. It launched on Monday, April 18 and will run for the next six weeks.